search
Back to results

How Does Magnesium Status Influence Calcium Homeostasis?

Primary Purpose

Magnesium Deficiency, Calcium Metabolism Disorders

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
vitamin D3
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Magnesium Deficiency focused on measuring vitamin D, cholecalciferol, bone mineral density, Magnesium deficiency, Calcium metabolism disorders

Eligibility Criteria

30 Years - 75 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • participants eligible for the study "Treatment of vitamin D insufficiency" are eligible for participation in the current sub-study

Exclusion Criteria:

  • identical to those covered in HSC #2009-0055

Sites / Locations

  • University of Wisconsin-Madison Hospital, Clinical Research Unit, Osteoporosis Research Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

High dose vitamin D

Low dose vitamin D

Placebo

Arm Description

50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.

800 IU vitamin D3 every day of an approximate 365-day treatment.

A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.

Outcomes

Primary Outcome Measures

Evaluate the associations between magnesium intake, magnesium stores, fractional magnesium absorption and calcium homeostasis.
To evaluate relationships between magnesium intake and fractional magnesium absorption at baseline and 12 months, among 60 women participating in HSC Protocol 2009-0055, and to assess whether vitamin D therapy influences magnesium absorption among these women. We will also evaluate whether data collected from less than 72 hours of urine following tracer administration permits accurate assessment of fractional magnesium absorption.

Secondary Outcome Measures

Does vitamin D therapy have a differential impact on calcium absorption that is dependent on magnesium stores?
To assess whether vitamin D therapy has a differential impact on calcium absorption, depending on magnesium stores. We will use data from all subjects participating in HSC Protocol 2009-0055 to evaluate whether magnesium status is a co-factor in the change in calcium absorption that occurs with vitamin D therapy.
Assessing relationships between magnesium status and bone mineral density.
Evaluate how magnesium status impacts the relationship between vitamin D levels and parathyroid hormone levels.

Full Information

First Posted
May 4, 2012
Last Updated
October 31, 2016
Sponsor
University of Wisconsin, Madison
Collaborators
National Institutes of Health (NIH), National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT01593501
Brief Title
How Does Magnesium Status Influence Calcium Homeostasis?
Official Title
How Does Magnesium Status Influence Calcium Homeostasis?
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison
Collaborators
National Institutes of Health (NIH), National Institute on Aging (NIA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators aim to recruit 60 women who have agreed to participate in an existing randomized, double-blind, placebo-controlled trial (Treatment of Vitamin D Insufficiency, HSC 2009-0055). In this trial, the investigators propose to evaluate the associations between magnesium intake, magnesium stores, fractional magnesium absorption and calcium homeostasis. The investigators will stratify 60 subjects in the sub-study, ensuring that approximately 20 subjects are randomized into each treatment arm (placebo, low-dose and high-dose vitamin D). The investigators already assess calcium homeostasis throughout the study by measuring bone mineral density, fractional calcium absorption, serum and urine calcium levels, among other tests. In the sub-study of 60 women, the investigators will evaluate whether habitually higher magnesium intake increases or decreases fractional calcium absorption. The investigators will evaluate the interplay between magnesium stores, vitamin D levels and serum parathyroid hormone levels. The investigators will directly assess magnesium stores using serum magnesium and 24-hour urine magnesium levels, and will measure magnesium absorption using the dual stable isotope approach.
Detailed Description
Use of serum magnesium isotopes to measure fractional magnesium absorption Four day food diaries to assess magnesium intake Standard urine and serum chemistries for remaining labs as noted above

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Magnesium Deficiency, Calcium Metabolism Disorders
Keywords
vitamin D, cholecalciferol, bone mineral density, Magnesium deficiency, Calcium metabolism disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
39 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High dose vitamin D
Arm Type
Active Comparator
Arm Description
50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
Arm Title
Low dose vitamin D
Arm Type
Active Comparator
Arm Description
800 IU vitamin D3 every day of an approximate 365-day treatment.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
Intervention Type
Dietary Supplement
Intervention Name(s)
vitamin D3
Other Intervention Name(s)
Cholecalciferol
Intervention Description
pharmaceutical grade D3
Primary Outcome Measure Information:
Title
Evaluate the associations between magnesium intake, magnesium stores, fractional magnesium absorption and calcium homeostasis.
Description
To evaluate relationships between magnesium intake and fractional magnesium absorption at baseline and 12 months, among 60 women participating in HSC Protocol 2009-0055, and to assess whether vitamin D therapy influences magnesium absorption among these women. We will also evaluate whether data collected from less than 72 hours of urine following tracer administration permits accurate assessment of fractional magnesium absorption.
Time Frame
0-12 months
Secondary Outcome Measure Information:
Title
Does vitamin D therapy have a differential impact on calcium absorption that is dependent on magnesium stores?
Description
To assess whether vitamin D therapy has a differential impact on calcium absorption, depending on magnesium stores. We will use data from all subjects participating in HSC Protocol 2009-0055 to evaluate whether magnesium status is a co-factor in the change in calcium absorption that occurs with vitamin D therapy.
Time Frame
0-12 months
Title
Assessing relationships between magnesium status and bone mineral density.
Time Frame
0-12 months
Title
Evaluate how magnesium status impacts the relationship between vitamin D levels and parathyroid hormone levels.
Time Frame
0-12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: participants eligible for the study "Treatment of vitamin D insufficiency" are eligible for participation in the current sub-study Exclusion Criteria: identical to those covered in HSC #2009-0055
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen E Hansen, M.D., M.S.
Organizational Affiliation
University of Wisconsin-Madison, Department of Medicine, Division of Rheumatology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Wisconsin-Madison Hospital, Clinical Research Unit, Osteoporosis Research Center
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24500940
Citation
Hansen KE, Nabak AC, Johnson RE, Marvdashti S, Keuler NS, Shafer MM, Abrams SA. Isotope concentrations from 24-h urine and 3-h serum samples can be used to measure intestinal magnesium absorption in postmenopausal women. J Nutr. 2014 Apr;144(4):533-7. doi: 10.3945/jn.113.186767. Epub 2014 Feb 5.
Results Reference
background

Learn more about this trial

How Does Magnesium Status Influence Calcium Homeostasis?

We'll reach out to this number within 24 hrs